All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Etentamig combined with daratumumab/dexamethasone for RRMM: Results from the phase I Kilimanjaro trial
By Ella Dixon
Bookmark this article
|
Etentamig (ABBV-383) is a BCMA- and CD3-directed bispecific antibody with previously demonstrated efficacy in treating heavily pretreated patients with RRMM as a monotherapy. At the 66th ASH Annual Meeting and Exposition, Rodriguez presented results from Arm C of Kilimanjaro (NCT05259839), an open-label, phase I dose-escalation and expansion trial.1 Arm C examined etentamig in combination with daratumumab and dexamethasone in patients with R/R MM who had received ≥3 prior lines of therapy. A total of 86 patients were treated with the triplet combination, with doses of etentamig of 20 mg (n = 37), 40 mg (n = 35), and 60 mg (n = 14).1 |
| Key learnings |
| In the dose escalation phase, 12 patients experienced a DLT, most commonly thrombocytopenia. Disease progression was the most common reason for treatment discontinuation (22%). |
| The most common hematologic TEAE was neutropenia, affecting 35% of patients in the 20 mg group and 57% in the 40 mg and 60 mg groups. Infections occurred in 67% of patients overall. |
| With a median follow-up of 7 months, the ORR was 71% overall and 83% in the 40–60 mg dose, with a median time to first response of 1 month. 28% of patients achieved sCR/CR, with the highest CR rate observed in the 40 mg group (40%). |
| In a heavily pretreated patient population, etentamig in combination with daratumumab and dexamethasone led to high ORR, with no unexpected safety signals compared with monotherapy, warranting further investigation in earlier lines of therapy. |
Abbreviations: AE, adverse event; ASH, American Society of Hematology; BCMA, B cell maturation antigen; CR, complete response; DLT, dose-limiting toxicity; MM, multiple myeloma; ORR, overall response rate; R/R, relapsed/refractory; sCR, stringent complete response; TEAE, treatment-emergent adverse event.
- Rodriguez C. ABBV-383 plus daratumumab-dexamethasone in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study. Oral abstract #496. 66th American Society of Hematology (ASH) Annual Meeting and Exposition; Dec 7–10, 2024; San Diego, US.
Your opinion matters
2 votes - 47 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox